Literature DB >> 25887072

Rebuttal of the Pro View: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD.

Linda F Fried1, Julia Lewis2.   

Abstract

Entities:  

Keywords:  CKD; albuminuria; biomarker; end point; risk factors; surrogate

Mesh：

Substances：

Year:  2015        PMID： 25887072      PMCID： PMC4455196          DOI： 10.2215/CJN.01610215

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  12 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.

Authors:  George L Bakris; Pantelis A Sarafidis; Matthew R Weir; Björn Dahlöf; Bertram Pitt; Kenneth Jamerson; Eric J Velazquez; Linda Staikos-Byrne; Roxzana Y Kelly; Victor Shi; Yann-Tong Chiang; Michael A Weber
Journal:  Lancet       Date:  2010-02-18       Impact factor: 79.321

3.  Combined angiotensin inhibition for the treatment of diabetic nephropathy.

Authors:  Linda F Fried; Nicholas Emanuele; Jane H Zhang; Mary Brophy; Todd A Conner; William Duckworth; David J Leehey; Peter A McCullough; Theresa O'Connor; Paul M Palevsky; Robert F Reilly; Stephen L Seliger; Stuart R Warren; Suzanne Watnick; Peter Peduzzi; Peter Guarino
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

Review 4.  The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.

Authors:  Marissa N Lassere
Journal:  Stat Methods Med Res       Date:  2007-10-09       Impact factor: 3.021

5.  Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria).

Authors:  Enyu Imai; Masakazu Haneda; Juliana C N Chan; Tetsu Yamasaki; Fumiaki Kobayashi; Sadayoshi Ito; Hirofumi Makino
Journal:  Nephrol Dial Transplant       Date:  2013-09-07       Impact factor: 5.992

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 7.  Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.

Authors:  Hiddo J Lambers Heerspink; Tobias F Kröpelin; Jarno Hoekman; Dick de Zeeuw
Journal:  J Am Soc Nephrol       Date:  2014-11-24       Impact factor: 10.121

8.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

9.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

10.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245
View more
  6 in total

Review 1.  Role of albumin and its modifications in glomerular injury.

Authors:  Shipra Agrawal; William E Smoyer
Journal:  Pflugers Arch       Date:  2017-07-22       Impact factor: 3.657

Review 2.  Biomarkers to Monitor Adherence to Gluten-Free Diet by Celiac Disease Patients: Gluten Immunogenic Peptides and Urinary miRNAs.

Authors:  Alessandro Paolini; Meysam Sarshar; Cristina Felli; Stefania Paola Bruno; Mohammad Rostami-Nejad; Francesca Ferretti; Andrea Masotti; Antonella Baldassarre
Journal:  Foods       Date:  2022-05-10

3.  Potential Role of N-Cadherin in Diagnosis and Prognosis of Diabetic Nephropathy.

Authors:  Hamad Ali; Mohamed Abu-Farha; Maha M Hammad; Sriraman Devarajan; Yousif Bahbahani; Irina Al-Khairi; Preethi Cherian; Zahra Alsairafi; Vidya Vijayan; Fahd Al-Mulla; Abdulnabi Al Attar; Jehad Abubaker
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-31       Impact factor: 6.055

4.  Urinary Exosomal MicroRNA Profiling in Incipient Type 2 Diabetic Kidney Disease.

Authors:  Yijun Xie; Yijie Jia; Xie Cuihua; Fang Hu; Meng Xue; Yaoming Xue
Journal:  J Diabetes Res       Date:  2017-09-05       Impact factor: 4.011

5.  Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients.

Authors:  Denis Delić; Claudia Eisele; Ramona Schmid; Patrick Baum; Franziska Wiech; Martin Gerl; Heike Zimdahl; Steven S Pullen; Richard Urquhart
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

6.  Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease.

Authors:  Sven Hoefman; Nelleke Snelder; Martijn van Noort; Alberto Garcia-Hernandez; Hartmut Onkels; Tobias E Larsson; Kirsten R Bergmann
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-09-14       Impact factor: 2.745
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.